Carpenter CC, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations
of an international panel. JAMA.1997;277:1962-1969.
Hammer SM, Katzenstein DA, Hughes MD.
et al. A trial comparing nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cells counts from 200 to 500 per cubic millimeter. N Engl J Med.1996;335:1081-1090.
Eron JJ, Benoit SL, Jemsek J.
et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients
with 200 to 500 CD4+ cells per cubic millimeter: North American HIV Working
Party. N Engl J Med.1995;333:1662-1669.
Kaplan JE, Masur H, Holmes KK.
et al. USPHS/IDSA guidelines for the prevention of opportunistic infections
in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis.1995;21 Suppl 1:S12-S31.
Ioannidis JP, Cappelleri JC, Skolnik PR, Lair J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med.1996;156:177-188.
Bozzette SA, Finkelstein DM, Spector SA.
et al. A randomized trial of three antipneumocystis agents in patients with
advanced human immunodeficiency virus infection. N Engl J Med.1995;332:693-699.
Nightingale SD, Cameron DW, Gordin FM.
et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med.1993;329:828-833.
Havlir DV, Dube MP, Sattler FR.
et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med.1996;335:392-398.
Pierce M, Crampton S, Henry D.
et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with
advanced acquired immunodeficiency syndrome. N Engl J Med.1996;335:384-391.
Powderly WG, Finkelstein D, Feinberg J.
et al. A randomized trial comparing fluconazole with clotrimazole troches
for the prevention of fungal infections in patients with advanced human immunodeficiency
virus infection. N Engl J Med.1995;332:700-705.
Spector SA, McKinley GF, Jacob P.
et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons
with AIDS. N Engl J Med.1996;334:1491-1497.
Medical Economics. Drug Topics Red Book . Montvale, NJ: Medical Economics; 1996.
Doyle A, Jefferys R, Kelly J. State AIDS Drug Assistance Programs: A National Status Report
on Access . Washington, DC, and New York, NY: National Alliance of State and
Territorial AIDS Directors and AIDS Treatment Data Network; July 10, 1997.
Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine . New York, NY: Oxford University Press; 1996.
Berk ML, Mafeo C, Schur CI. Research Design and Analysis Objectives, AIDS Cost and Services
Utilization Survey (ACSUS) Report No. 1 . Rockville, Md: Agency for Health Care Policy and Research; 1993.
AHCPR publication 93-0019.
Phair J, Munoz A, Detels R.
et al. The risk of Pneumocystis carinii pneumonia
among men infected with human immunodeficiency virus type 1. N Engl J Med.1990;322:161-165.
Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep.1992;41(RR-17):1-19.
National Technical Information Service. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release
P04 . Springfield, Va: National Technical Information Service; 1995.
Enger C, Graham N, Peng Y.
et al. Survival from early, intermediate, and late stages of HIV infection. JAMA.1996;275:1329-1334.
Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Renaldo Jr CR.The Multicenter AIDS Cohort Study. The Multicenter AIDS Cohort Study: rationale, organization, and selected
characteristics of the participants. Am J Epidemiol.1987;126:310-318.
Miettinen OS. Estimability and estimation in case-referent studies. Am J Epidemiol.1976;103:226-235.
Laird NM, Ware JH. Random effects model for longitudinal data. Biometrics.1982;38:963-974.
Miller DK, Homan SM. Determining transition probabilities. Med Decis Making.1994;14:52-58.
Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making.1983;3:419-458.
Brosgart C, Graig C, Hillman D.
et al. Final results from a randomized, placebo-controlled trial of the safety
and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal
mucosal disease. In: Program and abstracts of the XI International Conference on AIDS;
July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.301.
Hardy WD, Feinberg J, Finkelstein DM.
et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized
pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome:
AIDS Clinical Trials Group Protocol 021. N Engl J Med.1992;327:1842-1848.
National Technical Information Service. AIDS Cost and Services Utilization Survey: Public Use Tapes 4
and 5 . Springfield, Va: National Technical Information Service; 1994. No.
National Public Health and Hospital Institute. Hospital AIDS/HIV Survey . Washington, DC: The National Public Health and Hospital Institute;
Centers for Disease Control and Prevention. AIDS cases and annual rates per 100,000 population, by metropolitan
area 500,000 or more population. HIV/AIDS Surveill Rep.February 1993:7-8.
Bureau of the Census. Statistical Abstract of the United States . 115th ed. Washington, DC: US Bureau of the Census; 1995.
Torrance GW. Social preferences for health states: an empirical evaluation of three
measurement techniques. Socioecon Planning Sci.1976;10:128-136.
Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical
cohort. Ann Intern Med.1996;124:633-642.
Finkelstein DM, Williams PL, Molenberghs G.
et al. Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol.1996;12:38-45.
Sande MA, Carpenter CCJ, Cobbs CG.
et al. Antiretroviral therapy for adult HIV-infected patients: recommendations
from a state-of-the-art conference. JAMA.1993;270:2583-2589.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative
assessment. Med Decis Making.1994;14:259-265.
Freedberg KA, Tosteson ANA, Cohen CJ, Cotton DJ. Primary prophylaxis for Pneumocystis carinii
pneumonia in HIV-infected people with CD4 counts below 200/mm3:
a cost-effectiveness analysis. J Acquir Immune Defic Syndr.1991;4:521-531.
Freedberg KA, Hardy WD, Holzman RS, Tosteson ANA, Craven DE. Validating literature-based models with direct clinical trial results:
the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making.1996;16:29-35.
Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis
carinii pneumonia. JAMA.1991;266:820-824.
Freedberg KA, Cohen CJ, Barber TW. Preventing Mycobacterium avium complex infection
in patients with AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Retrovirol.1997;15:275-282.
Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis for systemic fungal
infections in patients with AIDS. Med Decis Making.1997;17:483-489.
Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients
with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS.1997;11:883-887.
Paltiel AD, Freedberg KA. Cost-effectiveness of preventing CMV disease in AIDS patients. Interfaces.In press.
Robbins GK, Cotton DJ. Cost-effectiveness of ganciclovir for prevention of CMV retinitis. In: Program and abstracts of the 4th Conference on Retroviruses and
Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 296.
Walmsley S, Mazzulli T, Shankaran P, Krajden M. Predictive value of a single CMV PCR and subsequent development of
end organ disease. In: Program and abstracts of the 4th Conference on Retroviruses and
Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 702.
Kaspar R, DuBois DB. The clinical course of severely immunocompromised patients achieving
a re-expansion of CD4 cells to above 50 cells/mm3 following antiretroviral
therapy for HIV-1. In: Program and abstracts of the 4th Conference on Retroviruses and
Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 656.
Jacobson MA, Kramer F, Pavan PR, Owens S, Pollard R.The NIAID ACTG Protocol 266 Team. Failure of highly active antiretroviral therapy to prevent CMV retinitis
despite marked CD4 count increase. In: Program and abstracts of the 4th Conference on Retroviruses and
Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 726.
Centers for Disease Control. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections
in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep.1997;46(RR-12):1-46.